Substance / Medication

Eletriptan

Overview

Active Ingredient
eletriptan
RxNorm CUI
231049

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
WITHDRAWN: Eletriptan for acute migraine.
Smith L A, Oldman A D, McQuay H J et al. · Cochrane Database Syst Rev · 2007
PMID: 17636718Meta-AnalysisFull text (PMC)
Eletriptan for acute migraine.
Smith L A, Oldman A D, McQuay H J et al. · Cochrane Database Syst Rev · 2001
PMID: 11687056Meta-Analysis
Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.
Kim Yu Kyong, Shin Kwang-Hee, Alderman Jeffrey et al. · Drug Des Devel Ther · 2018
PMID: 29497279RCTFull text (PMC)
Headache treatment after electroconvulsive treatment: a single-blinded trial comparator between eletriptan and paracetamol.
Kertesz Diana Paleacu, Trabekin Olga, Vanetik Marnina Swartz · J ECT · 2015
PMID: 25181019RCT
Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study.
Almas Mary, Tepper Stewart J, Landy Stephen et al. · Cephalalgia · 2014
PMID: 23946318RCT
Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes.
Silberstein Stephen D, Cady Roger K, Sheftell Fred D et al. · Headache · 2007
PMID: 17501848RCT
Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries.
Newman Christopher M H, Starkey Ian, Buller Nigel et al. · Eur J Clin Pharmacol · 2005
PMID: 16151760RCT
Quantitative analysis of eletriptan in human plasma by HPLC-MS/MS and its application to pharmacokinetic study.
Ponnuru Venkata Suresh, Challa B R, Nadendla Ramarao · Anal Bioanal Chem · 2011
PMID: 21892641Observational
Study of forced degradation behavior of eletriptan hydrobromide by LC and LC-MS and development of stability-indicating method.
Jocić Biljana, Zecević Mira, Zivanović Ljiljana et al. · J Pharm Biomed Anal · 2009
PMID: 19250786Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Eletriptan (substance)
SNOMED CT
410843003
UMLS CUI
C0759933
RxNorm CUI
231049

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.